Enovis (ENOV) Cash from Financing Activities (2010 - 2026)
Enovis (ENOV) reported Cash from Financing Activities of $26.0 million for Q2 2026, down 49.16% year-over-year from $51.2 million in Q2 2025, and up 135.69% quarter-over-quarter from -$72.9 million in Q4 2025.
Enovis (ENOV) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Enovis (ENOV) has 17 years of Cash from Financing Activities data on file, last reported at $26.0 million in Q2 2026.
- Cash from Financing Activities for Q2 2026 came in at $26.0 million, down 49.16% year-over-year; the trailing twelve-month figure through Apr 2026 was -$77.6 million (down 331.74% YoY), and the FY2025 annual result was -$52.4 million, down 106.19% from the prior year.
- Cash from Financing Activities grew to $26.0 million in Q2 2026 per ENOV's latest filing, from -$72.9 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $864.5 million in Q1 2024 and troughed at -$495.5 million in Q3 2022.
- A 5-year average of $28.4 million and a median of $2.5 million in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 3429.02% in 2024, then slumped 24837.16% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $41.6 million in 2022, then plunged by 93.3% to $2.8 million in 2023, then plunged by 819.97% to -$20.1 million in 2024, then slumped by 263.12% to -$72.9 million in 2025, then surged by 135.69% to $26.0 million in 2026.
- Business Quant data shows ENOV's Cash from Financing Activities at $26.0 million in Q2 2026, -$72.9 million in Q4 2025, and -$36.9 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -2.09 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -26.93 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -25.00 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | -97.90 Mn |
| 10 | Enovis | 1.26 Bn | 1.23 Bn | 365.49 Mn | 26.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 26.02 Mn |
| Apr 3, 2026 | 26.02 Mn |
| Dec 31, 2025 | -72.92 Mn |
| Dec 31, 2025 | -72.92 Mn |
| Oct 3, 2025 | -36.91 Mn |
| Oct 3, 2025 | -36.91 Mn |
| Jul 4, 2025 | 6.23 Mn |
| Jul 4, 2025 | 6.23 Mn |
| Apr 4, 2025 | 51.19 Mn |
| Apr 4, 2025 | 51.19 Mn |
| Dec 31, 2024 | -20.08 Mn |
| Dec 31, 2024 | -20.08 Mn |
| Sep 27, 2024 | -148,000.00 |
| Sep 27, 2024 | -148,000.00 |
| Jun 28, 2024 | 2.51 Mn |
| Jun 28, 2024 | 2.51 Mn |
| Mar 29, 2024 | 864.54 Mn |
| Mar 29, 2024 | 864.54 Mn |
| Dec 31, 2023 | 2.79 Mn |
| Dec 31, 2023 | 2.79 Mn |